Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

Clinical Journal of the American Society of Nephrology : CJASN
Tracy McGowanMarsha Wolfson

Abstract

Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis. Thirty-eight patients, enrolled from nine centers in the United States, were > or =18 yr of age and had hemoglobin <11.0 g/dl and GFR 12 to 60 ml/min per 1.73 m(2). Patients received one of four epoetin alfa dosing regimens: 50 IU/kg three times per week, 10,000 IU once weekly, or 20,000 IU every 2 wk for 36 d or 40,000 IU every 4 wk for 64 d. Each regimen provided a similar dosage of epoetin alfa over 4 wk. Dosage adjustments were not permitted. Drug exposure to epoetin alfa over 4 wk, based on area under the curve, was somewhat higher with the extended interval regimens compared with the three-times-weekly regimen. Mean change in hemoglobin during the study period was similar for all regimens. No patients were transfused. Three patients experienced five serious adverse events, none of which was considered treatment related. Extended dosing interval regimens of epoetin alfa ...Continue Reading

References

Dec 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·V S LimR L DeGowin
Jul 1, 2004·Clinical Nephrology·R ProvenzanoUNKNOWN POWER Study Group
Jun 30, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Michael GermainMario Curzi
Jan 27, 2007·Clinical Pharmacokinetics·Per Olsson-GisleskogJuan Jose Perez-Ruixo
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Robert BenzMarsha Wolfson
Apr 11, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Bruce SpinowitzUNKNOWN Epoetin Alfa Extended Dosing Study Group

❮ Previous
Next ❯

Citations

Oct 8, 2009·Clinical Journal of the American Society of Nephrology : CJASN·Pablo E PergolaPeter Bowers
Feb 27, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Pablo E PergolaPeter Bowers
Sep 30, 2009·World Journal of Gastroenterology : WJG·Rosario Moreno LópezFernando Gomollón García
Jul 28, 2009·Lancet·Hiroshi NonoguchiTakeshi Nakanishi
Oct 24, 2015·Journal of the American Society of Nephrology : JASN·Louis HoldstockAlexander R Cobitz
Oct 10, 2008·Orvosi hetilap·Zoltán KissIstván Kiss
Jun 9, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas ThessThomas Schlake
Jan 10, 2017·The Cochrane Database of Systematic Reviews·Deirdre HahnElisabeth M Hodson
Jun 27, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Rowan G Walker
Jan 9, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Richard J GlassockSilvio H Barberato
Mar 12, 2010·Journal of Clinical Pharmacology·Kenneth MaieseJinling Hou
Mar 13, 2018·Journal of Korean Neurosurgical Society·Won-Sang ChoUNKNOWN Korean Stroke Society and Korean Academy of Rehabilitation Medicine
Apr 17, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Meredith A Atkinson, Bradley A Warady

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.